Puneet Bansal, MD
Cardiovascular Disease · Missoula, MTNPI 1417230855
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $929 and has fallen 85.0% since, to $139 in 2025.
Across 141 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$362
- Johnson & Johnson$357
- Amgen$320
- E.r. Squibb & Sons, L.L.C.$245
- Merck$212
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$140
- plus $864 from 18 others
What the payments were for
- Food & beverage$2,493100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 20 | $362 |
| Johnson & Johnson | 18 | $357 |
| Amgen | 22 | $320 |
| E.r. Squibb & Sons, L.L.C. | 13 | $245 |
| Merck | 14 | $212 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $140 |
| Spinefrontier, Inc. | 3 | $139 |
| Sanofi-aventis U.S. LLC | 5 | $139 |
| AstraZeneca | 10 | $126 |
| Regeneron Healthcare Solutions, Inc. | 7 | $112 |
| Esperion Therapeutics, Inc. | 3 | $59 |
| Actelion Pharmaceuticals US, Inc. | 2 | $49 |
| Sanofi | 2 | $33 |
| Pfizer | 2 | $26 |
| Boehringer Ingelheim | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Heartflow, Inc. | 1 | $21 |
| GE HealthCare | 1 | $19 |
| Lemaitre Vascular, Inc. | 1 | $18 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| Preventice Services, LLC | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
How this compares
$2,500 in reported general payments places this provider in the 65th percentile of 49 cardiovascular disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 345 | $413,721 |
| XareltoRivaroxaban | 66 | $89,355 |
| JardianceEmpagliflozin | 42 | $52,643 |
| EntrestoSacubitril/Valsartan | 29 | $41,395 |
| Repatha SureclickEvolocumab | 34 | $24,302 |
| Repatha SyringeEvolocumab | 23 | $11,131 |
| Ranolazine ErRanolazine | 32 | $5,463 |
| Metoprolol Succinate | 278 | $3,908 |
| Amiodarone Hcl | 70 | $2,958 |
| Atorvastatin Calcium | 268 | $2,860 |
| Rosuvastatin Calcium | 121 | $2,830 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 89 | $2,621 |
| Ezetimibe | 82 | $1,865 |
| Amlodipine Besylate | 138 | $1,376 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 99 | $1,363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $413,721345 claims |
| Johnson & JohnsonXarelto | $357 | $89,35566 claims |
| Boehringer IngelheimJardiance | $24 | $52,64342 claims |
| NovartisEntresto | $362 | $41,39529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 49 cardiovascular disease providers in Montana.
Other cardiovascular disease in Missoula
- Jocelyn SpoonMissoula$17K
- Patricia KellyMissoula$12K
- Newton CoutinhoMissoula$10K
- Michael ReedMissoula$8K
- Gregory WoodMissoula$6K
- Morgan KelloggMissoula$4K
- Ashley MaysMissoula$4K
- Matthew WeissMissoula$3K
- Alexander JehleMissoula$2K
- Jon McGregorMissoula$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.